ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen? Clinical Trial
biospace
March 08, 2018?BioTime, Inc. announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ongoing OpRegen??clinical trial -
BioTime Forms New Subsidiary AgeX Therapeutics to Develop its Programs Focused on Human Aging
americanpharmaceuticalreview
April 07, 2017BioTime, Inc. has announced the formation of AgeX Therapeutics, Inc., which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology.
Pharma Sources Insight January 2025
